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1. Introduction 
Autism (MIM 209850) comprises a heterogeneous group of disorders with a complex genetic 
etiology, characterized by impairments in reciprocal social communication and  presence of 
restricted, repetitive and stereotyped patterns of behavior [1]. With an early  onset prior to 
age 3 and prevalence as high as 0.9–2.6% [2,3], autism occurs predominantly  in males, with 
a ratio of male: female of 4 to 1. It is one of the leading causes of childhood  disability and 
inflicts serious suffering and burden for the family and society [4].  
Diagnosis of autism is based on expert observation and assessment of behavior and 
cognition, not etiology or pathogenic mechanism. This is further emphasized by the current 
trend in the DSM-V, in which the category of Asperger syndrome is removed and the 
diagnostic criteria for autism are modified under the new heading of autism spectrum 
disorder (ASD). The change in diagnostic criteria is not based on known similarities or 
differences in causation between these clinically defined categories, but rather on the 
consensus of opinions of expert clinicians. For autism, several diagnostic instruments are 
available. Two are commonly used in autism research: the Autism Diagnostic Interview-
Revised (ADI-R) that is a semi-structured parent interview [5], and the Autism Diagnostic 
Observation Schedule (ADOS) uses observation and interaction with the child(ren) [6]. The 
Childhood Autism Rating Scale (CARS) is used widely in clinical environments to assess 
severity of autism based on observation of children [7]. The M-CHAT was developed in the 
late 1990s as a first-stage screening tool for ASD in toddlers’ age 18 to 24 months, with a 
sensitivity of 0.87 and a specificity of 0.99 in American children [8, 9]. 
2. Clinical heterogeneity of ASD 
Autistic conditions are a spectrum of disorders, rather than a distinct clinical disorder, 
which means that the symptoms can be present in a variety of combinations with a range of 
severity. The disease has variable cognitive manifestations, ranging from a non-verbal child 
with mental retardation to a high-functioning college student with above average IQ with 
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inadequate social skills [10]. Clinical heterogeneity of autism showed three major categories: 
idiopathic autism, autistic spectrum disorder (ASD), and syndromatic autistics that usually 
resulted from an identified syndrome with known genetic etiology. Traditionally, ASD 
includes autism, Asperger syndrome, where language appears normal, Rett syndrome and 
pervasive developmental disorder not otherwise specified (PDD-NOS), in which children 
meet some but not all criteria for autism. Rett syndrome (RTT), occurring almost exclusively 
in females, is characterized by developmental arrest between 5 and 18 months of age, 
followed by regression of acquired skills, loss of speech, stereotypic movements (classically 
of the hands), microcephaly, seizures, and intellectual difficulties. These disorders share 
deficits in social communication and show variability in language and repetitive behavior 
domains [1]. Autistic individuals may have symptoms that are independent of the 
diagnosis. Mental retardation is present in approximately 75% of cases of autism, seizures in 
15 to 30% of cases, attention deficit hyperactivity disorder (ADHD) in 59-75% of cases, 
schizophrenia (SZ) in 5% of cases, obsessive-compulsive disorder (OCD) in about 60% of 
cases and electroencephalographic abnormalities in 20 to 50% of cases [11]. In addition, 
approximately 15 to 37% of cases of autism have a comorbid medical condition such as 
epilepsy, sensory abnormalities, motor abnormalities, sleep disturbances, and 
gastrointestinal symptoms. Five to 14% of cases had a known genetic disorder or 
chromosomal anomaly. The 4 most common conditions associated with autistic phenotypes 
are fragile X syndrome, tuberous sclerosis, 15q duplications, and untreated phenylketonuria. 
Other conditions associated with autistic phenotypes include Angelman syndrome, Cowden 
disease, Smith-Lemli-Opitz syndrome, cortical dysplasia-focal epilepsy (CDFE) syndrome, 
Neurofibromatosis, and X-linked mental retardation.  
3. Autism is a complex genetic disorder 
It is widely held that autism is largely genetic in origin; several dozen autism susceptibility 
genes have been identified in the past decade, collectively accounting for about 20% of 
autistic cases. There is strong evidence from twin and family studies for the importance of 
complex genetic factors in the development of autism [12, 13]. Family studies have shown 
that a recurrence rate of autism in siblings of affected proband is as high as 8–10% [12, 14]. 
Thus, the recurrence risk in siblings is roughly 100 times higher than that found in the 
general population. The substantial degree of familial clustering in ASD could reflect shared 
environmental factors, but twin studies strongly point to genetics. Several epidemiological 
studies among sex-matched twins have clearly demonstrated significant differences of 
concordance rates in the monozygotic (MZ) and dizygotic (DZ) twins. The largest of these 
studies [15] found that 60% of the MZ pairs were concordant for autism compared with 
none of the DZ pairs, suggesting a heritability estimate of >90% assuming a multifactorial 
threshold model. This is what is observed in every twin study in autism, and is overall 
consistent with heritability estimates of about 70–80% [15, 16]. One exception is a very recent 
study with a large sample of twins, which, despite showing a concordance of about 0.6 for 
MZ twins and 0.25 for DZ twins, comes to the conclusion that shared environment plays a 
larger role than genetic factors [17]. However, the question of how a shared environment 
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would have a more major role than genetics is not clear. Moreover, studies in families show 
that first-degree relatives of an autistic proband have a markedly increased risk for autism 
relative to the population, consistent with a strong familial or genetic effect observed in 
twins [18]. This is not to dispute the role of the environment but to emphasize that genes 
play an important role. Similar to other common diseases with genetic contributions, autism 
was thought to fit a model in which multiple variants, each with small to moderate effect 
sizes, interact with each other and perhaps in some cases, environmental factors, to lead to 
autism; a situation referred to as complex genetics [13]. 
4. Genetic heterogeneity of autism 
Although autism is highly heritable, the identification of candidate genes has been hindered 
by the heterogeneity of the disease. Autism genetics is highly complex, involving many 
genes/loci and different genetic variations, including translocation, deletion, single 
nucleotide polymorphism (SNP) and copy number variation (CNV) [13, 19, 20]. The most 
obvious general conclusion from all of the published genetic studies is the extraordinary 
etiological heterogeneity of autism. No specific gene accounts for the majority of autism; 
rather, even the most common genetic forms account for not more than 1–2% of cases [21]. 
Further, these genes, including those mentioned earlier, represent a diversity of molecular 
mechanisms that include cell adhesion, neurotransmission, synaptic structure, RNA 
processing/splicing, and activity-dependent protein translation. Genetic heterogeneity of 
autistic cases has been documented by identification of single gene mutations and genomic 
variations including CNV. The mutant genes identified from autistic patients are: FMR1, 
MECP2, CNTNAP2, PTEN, DHCR7, CACNA1C, UBE3A, TSC2, NF1, ARX, NLGN3, NLGN4, 
NRXN1, FOXP1, FOXP2, GRIK2, and SHANK3 (Table 1). Genomic variation including copy 
number deletion or duplication at loci of 1q21.2, 1q42.2, 2q31.1, 3p25.3, 7q11.23, 7q22.1, 
7q36.3, 11q13.3, 12q14.2, 15q11-13, 16p11.2, 16q13.3, 17q11.2, 17q12, 17q21.32, 22q13.33, or 
Xp22.11 may also associate with autism. 
5. Genotype/phenotype correlation in ASD 
The presence of genetic and phenotypic heterogeneity in autism with a number of 
underlying pathogenic mechanisms is highlighted in this current review. There are at least 
three phenotypic presentations with distinct genetic underpinnings: (1) autism with 
syndromic phenotype characterized by rare, single-gene defects (Table 2); (2) broad autistic 
phenotypes caused by genetic variations in single or multiple genes, each of these variations 
being common and distributed continually in the general population but resulting in variant 
clinical phenotypes when it reaches a certain threshold through complex gene-gene and 
gene-environment interactions; and (3) severe and specific phenotype caused by 'de-novo' 
mutations in the patient or transmitted through asymptomatic carriers of such mutations 
(Table 3) [48, 49]. Understanding the neurobiological processes by which genotypes lead to 
phenotypes, along with the advances in developmental neuroscience and neuronal 
networks at the cellular and molecular level, are paving the way for translational research 
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involving targeted interventions of affected molecular pathways and early intervention 
programs that promote normal brain responses to stimuli and alter the developmental 
trajectory [50]. Recent genetic results have improved our knowledge of the genetic basis of 
autism. Nevertheless, identification of phenotypic markers remains challenging due to 
phenotypic and genotypic heterogeneity. 
 
Gene Genetic alteration Location Reference 
FMR1 The number of CGG in FMR1 alleles 
is classified as intermediate mutation 
(45 to 55), premutation (55 to 200), or 
full mutation (＞200) 
5’untranslated region 22-24 
MECP2 T158M, T158A Missense mutation 25 
CNTNAP2 3709delG Exon 22 26 
G731S, I869T  
R1119H, D1129H, I1253T, T1278I 
Exon 14, 17 
Exon 20, 21, 23, 24 
27 
H275A Exon 6 28 
CNV (microdeletion) Promoter 29 
PTEN Deletion Exon 2 30 
CACNA1C G406R Missense mutation 31 
UBE3A D15S122 5' end of UBE3A 32, 33 
TSC2 SNP Intron 4, 9; exon 40 34 
NF1 SNP Intron 27 35 
NLGN3 R451C Missense mutation 36, 37 
NLGN4 1186insT Frameshift mutation 37 
NRXN1 De novo 320-kb deletion Promoter and initial 
coding exons 
38, 39 
Missense structural variant  Neurexin1ß signal 
peptide region 
40 
FOXP1 De novo intragenic deletion Exons 4-14 41 
FOXP2 Del CAA;  Exon 5 42, 43 
Frequency of the TT allele Intron 15 
GRIK2 SNP M867I 44 
SHANK3 De novo Q321R Stop codon  45 
1-bp insertion Exon 11  46 
De novo 7.9-Mb deletion 22q13.2-qter 47 
Table 1. Genetic alteration identified from autism 
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Gene/loci Chromosome Phenotype 
(human/mouse) 
Mechanism involved Risk of 
autism 
Reference 
CNTNAP2 7q35-q36.1 Recessive EPI 
syndrome, ASD, 
ADHD, TS, OCD
Chromosomal rearrangements and 
large deletions, disruption of the 
transcription factor FOXP2, SNP 
Not 
conclusive 
51-54 
CHD7 8q12.1 CHARGE  Mutations/deletions of gene CHD7, 
Chromatin remodeling; disruption of 
the transcription factor FOXP2; SNP; 
15–50% 55, 56 
TSC1 9q34.13 Tuberous 
Sclerosis type I. 
Mutation in gene TSC1 and subsequent 
hyperactivation of the downstream 
mTOR pathway, resulting in increased 
cell growth and proliferation. 
Not 
conclusive 
57 
PTEN 10q23.31 Cowden disease. Mutation of gene PTEN Not 
conclusive 
30 
DHCR7 11q13.4 Smith-Lemli-
Opitz syndrome 
Mutations of gene DHCR, leading to a 
deficiency of cholesterol synthesis and 
an accumulation of 7-
dehydrocholesterol 
15–50%  
 
3% 
58-60 
 
61, 62 
CACNA1C 12p13.33 Timothy 
syndrome.  
Missense mutations in the calcium 
channel gene CACNA1H  
Not 
conclusive 
63 
UBE3A 15q11.2 Angelman 
syndrome 
Maternal deletion, paternal UPD, 
deletions and epimutations at IC, 
mutations of UBE3A, Lack of 
expression of maternally expressed 
gene UBE3A  
Not 
conclusive  
32, 33 
TSC2 16p13.3 Tuberous 
Sclerosis type II 
Mutation in gene TSC2 and subsequent 
hyperactivation of the downstream 
mTOR pathway, resulting in increased 
cell growth and proliferation. 
Not 
conclusive 
57 
NF1 17q11.2 Neurofibromatosis Polymorphisms within the intron-27, 
including the (AAAT)(n) and two 
(CA)n 
Not 
conclusive 
35 
DMD Xp21.2 Duchenne muscular 
dystrophy 
Mutations of DMD gene resulting in 
absence of dystrophin protein  
Not 
conclusive 
64 
ARX Xp21.3 LIS, XLID, EPI, 
ASD 
Naturally occurring mutations. 
Nonsense mutations, polyalanine tract 
expansions and missense mutations 
Not 
conclusive 
65 
FMR1 Xq27.3 Fragile X 
syndrome 
CGG repeat expansion and DNA 
methylation of FMR1 gene, reduced 
FMR1 expression  
60–67% in 
males, 23% 
in female 
66 
MECP2 Xq28 Rett syndrome Mutations in MECP2 and CDKL5 Overlap in 
symptoms  
Infancy 
67, 68 
Abbreviations: LIS, lissencephaly; XLID, X-linked intellectual disability; EPI, epilepsy; OCD, obsessive compulsive 
disorder; TS, Tourette syndrome; ADHD, attention deficit hyperactivity disorder. 
Table 2. Autism plus syndromic ASD caused by rare, single-gene disorders 
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Gene Chromosome Phenotype 
(human/mou
se) 
Mechanism involved in ASD Reference 
NRXN1 2p16.3 ASD, ID, 
SCZ, 
Language 
delay 
De novo 320-kb deletion that removes the 
promoter and initial coding exons of the NRXN1 
gene, resulting in deletion of neurexin 1a 
39 
Missense structural variants in the neurexin 1b 
signal peptide region 
40 
CNV 69, 70 
Translocations and intragenic rearrangements 
in or near NRXN1gene 
71, 72 
FOXP1 3p13 ID, ASD, SLI De novo intragenic deletion encompassing exons 
4-14 of FOXP1, de novo nonsense mutation 
(c.1573C>T) in the conserved fork head DNA-
binding domain 
73 
GRIK2 6q16.3 ASD,  
Recessive ID 
SNP1 and SNP2 of gene GRIK2 were associated 
with autism 
74 
FOXP2 7q31.1 ASD, SLI Directly bind intron 1 of the CNTNAP2 gene 
and regulate its expression 
74 
 11p15.5 Beckwith- 
Wiedemann 
syndrome 
Overexpression of paternally expressed IGF2, 
due to a gain of DNA methylation at paternal 
allele of IC1 and suppression of maternally 
expressed suppressing factor CDKN1C  
75 
 15q11-q13 Prader-Willi 
syndrome 
Paternal deletions, maternal UPD at15q11–13, 
deletions and epimutations of IC, translocations 
disrupting SNRPN 
 
76, 77 
Maternal 
duplication of 
15q11-13 
region 
Maternal duplications of 15q11-13 region 78 
SHANK3 22q13.33 ASD Mutation at an intronic donor splice site, one 
missense mutation in the coding region 
79 
NLGN4X Xp22.32-
p22.31 
ASD, ID, TS, 
ADHD 
Frameshift mutation (1186insT) 37 
NLGN3 Xq13.1 ASD R451C mutation within the esterase domain of 
neuroligin 3 
36, 37 
Abbreviations: ID, intellectual disability; SCZ, schizophrenia; TS, Tourette syndrome; SLI, speech and language 
impairment; ADHD, attention deficit hyperactivity disorder 
Table 3. Severe and specific phenotype with rare variants of genes 
6. Copy number variation (CNV): A paradigm shift in autism  
The strong genetic contribution shown in family studies and the association of cytogenetic 
changes, but apparent lack of common risk factors in autism, led to a hypothesis that rare 
sub-microscopic unbalanced changes in the form of CNVs likely contribute to the autism 
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phenotype. With the development of microarrays capable of scanning the genome at sub-
microscopic resolution, there is accumulating evidence that multiple CNVs contribute to the 
genetic vulnerability to autism [80]. de novo CNV has been identified in up to 7–10% of 
sporadic autism [81, 82], but are less frequent in multiplex families, in which CNV accounts 
only for about 2% of families screened [80, 83]. This could possibly suggest different genetic 
liabilities in simplex and multiplex autism. Recurrent CNVs at 15q11-13 (1-3% of autism 
patients), 16p11 (1% of autism patients), and 22q11-13 have been confirmed in multiple 
studies [80, 83-86]. This hypothesis also has been proven largely successful in identifying 
autism-susceptibility candidate genes, including gains and losses at SHANK2 [87], SHANK3 
[88], NRXN1 [13], NLGN3 and NLGN4 [37], and PTCHD1 [89, 90]. Neurexins and neuroligins 
are synaptic cell-adhesion molecules (CAMs) that connect pre- and postsynaptic neurons at 
synapses, mediate trans-synaptic signaling, and shape neural network properties by 
specifying synaptic functions. The Shank family of proteins provides scaffolding for 
signaling molecules in the postsynaptic density of glutamatergic synapses. Genes encoding 
CAMs play crucial roles in modulating or fine-tuning synaptic formation and synaptic 
specification. Localization and interacting proteins at the synapse is shown in Figure 1.  
 
Figure 1. Localization of cell-adhesion molecules and their interacting proteins at the synapse. Proteins 
associated with ASD are underlined.  
It is apparent that many different loci, each with a presumably unique yet subtle 
contribution to neurodevelopment, underlie the phenotype of autism. These observations 
have resulted in a paradigm shift away from the previously held “common disease-common 
variant” hypothesis to a “common disease-rare variant” model for the genetic architecture 
of autism. The central tenet of this model suggests a role for multiple, rare, highly penetrant, 
genetic risk factors for ASD, many of which are in the form of CNV. To make sense of the 
contribution of CNVs to autism, a “threshold” model has been proposed [80]. The model 
posits that different CNVs exhibit different penetrance depending on the dosage sensitivity 
and function (relative to autism) of the gene(s) they affect. Some CNVs have a large impact 
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on autism susceptibility and these are typically de novo in origin, cause more severe autistic 
symptoms, are more prevalent among sporadic forms of autism, and are less influenced by 
other factors like gender and parent of origin. Other CNVs have moderate or mild effects 
that probably require other genetic (or non-genetic) factors to take the phenotype across the 
autistic threshold.  
7. Epigenetics plays an important role in autism 
In addition to structural genetic factors that play causative roles for autism, environmental 
factors also play an important role in autism by influencing fetal or early postnatal brain 
development, directly or via epigenetic modifications. Epigenetic modifications include 
cytosine methylation, post-translational modification of histones, small interfering RNA  
and genomic imprinting. Involvement of epigenetic factors in autism is demonstrated by the 
central role of epigenetic regulatory mechanisms in the pathogenesis of Rett syndrome and 
fragile X syndrome (FXS), both are the monogenic disorders resulted from single gene 
defects and commonly associated with autism [38-40]. FXS is a result of a triplet expansion 
of CGG repeats at the 5’ untranslated region of FMR1 gene, which encodes the FMRP 
(fragile X mental retardation protein). FMRP is proposed to act as a translation regulator of 
specific mRNAs in the brain and involved in synaptic development and maturation, 
through its nucleo-cytoplasmic shuttle activity as an RNA-binding protein. It has been 
shown that FMRP uses its arginine-glycine-glycine (RGG) box domain to bind a subset of 
mRNA targets that form a G-quadruplex structure. FMRP has also been shown to undergo 
the post-translational modifications of arginine methylation and phosphorylation [91, 92]. 
Our recent study demonstrated that alteration of methylation patterns at loci of Neurex1 and 
ENO2 are associated with autism [Wang and Zhong, manuscript in preparation].  
Genomic imprinting is the classic example of regulation of gene expression via epigenetic 
modifications, such as hypemethylation, that leads to parent of origin-specific gene 
expression. In addition, a growing number of genes that are not imprinted are regulated by 
DNA methylation, including Reelin (RELN) [41, 93-96], which has been considered as a 
candidate for autism. Several of the linkage peaks overlap or are in close proximity to 
regions that are subject to genomic imprinting on chromosomes 15q11-13, 7q21-31.31, 
7q32.3-36.3 and possibly 4q21-31, 11p11.2-13 and 13q12.3, with the loci on chromosomes15q 
and 7q demonstrating the most compelling evidence for a combination of genetic and 
epigenetic factors that confer risks for autism [97-101]. Genes in the imprinted cluster on 
chromosome 15q11–13 include MKRN3, ZNF127AS, MAGE12, NDN, ATP10A, GABRA5, 
GABRB3, and GABRG3 [102, 103]. Genes in the imprinted cluster on chromosome 7q21.3 
include SGCE, PEG10, PPP1R9A, DLX5, CALCR, ASB4, PON1, PON2, and PON3 [104, 
105]. 
Research has recently focused on the connections between the immune system and the early 
development of brain, including its possible role in the development of autism [106]. 
Immune aberrations consistent with a deregulated immune response may target neuronal 
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development and differentiation [107, 108]. Our study has suggested that a close contact 
with natural rubber latex (NRL) could trigger an immunoreaction to Hevea brasiliensis 
(Hev-b) proteins in NRL and resulted in autism [109]. This led us to a hypothesis that 
immune reactions triggered by environmental factors could damage synapse formation and 
neuronal connections, which would result in missing normal structure or function of 
synaptic proteins that are encoded by genes NLGNs, NRXN1, CNTNAPs, SHANKs, or in 
deregulation of gene expression of FMR1, PTEN, FOXPs, and GRIK2.  
8. Converging molecular pathways of autism 
Autism is a heterogeneous disorder with a fundamental question of whether autism 
represents an etiologically heterogeneous disorder in which a myriad of genetic or 
environmental risk factors perturb common underlying molecular pathways in the brain 
[110]. Two recent studies have suggested there could be convergence at the level of 
molecular mechanisms in autism. The first study on molecular convergence in autism 
identified protein interactors of known autism or autism-associated genes [111]. This 
interactome revealed several novel interactions, including between two autism candidate 
genes, SHANK3 and TSC1. The biological pathways identified in this study include synapse, 
cytoskeleton and GTPase signaling, demonstrating a remarkable overlap with those 
identified by the gene expression. The second, an analysis of gene expression in postmortem 
autism brain, provides strong evidence for a shared set of molecular alterations in a majority 
of cases of autism. This included disruption of the normal gene expression pattern that 
differentiates frontal and temporal lobes and two groups of genes deregulated in autistic 
brains: one related to neuronal function, and the other related to immune/inflammatory 
responses [111]. Genes associated with neuronal function were enriched in metabolic 
signal pathways, providing evidence that these changes were causal, rather than the 
consequence of the disease [112]. In contrast, the immune/inflammatory changes did not 
show a strong genetic signal, indicating a non-genetic etiology for this process and 
implicating environmental or epigenetic factors instead. These results provide strong 
evidence for converging molecular abnormalities in autism, and implicating transcriptional 
and splicing deregulation as underlying mechanisms of neuronal dysfunction in this 
disorder. 
9. In summary 
Autism is a heterogeneous set of brain developmental disorders with complex genetics, 
involving interactions between genetic, epigenetic and environmental factors. The 
heterogenerous genetics involves many genes/loci and different genetic variations in autism, 
such as deletion, translocation, SNP and CNV. Recent studies have also suggested there 
could be convergence at the level of molecular mechanisms in autism. Although the genetic 
basis is well documented, considering phenotypic and genotypic heterogeneity, 
correspondences between genotype and phenotype have yet to be well established. 
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